|
Originally published In Press as doi:10.1074/jbc.C300012200 on January 21, 2003
J. Biol. Chem., Vol. 278, Issue 15, 12605-12608, April 11, 2003
ACCELERATED PUBLICATION
Neutralization of Circulating Vascular Endothelial Growth Factor
(VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria*
Hikaru
Sugimoto ,
Yuki
Hamano §,
David
Charytan ,
Dominic
Cosgrove¶,
Mark
Kieran ,
Akulapalli
Sudhakar, and
Raghu
Kalluri**
From the Program in Matrix Biology, Divisions of Gastroenterology
and Nephrology, Department of Medicine and the Cancer Center, Beth
Israel Deaconess Medical Center and Harvard Medical School, Boston,
Massachusetts 02215, the ¶ Gene Expression Laboratory, Boystown
National Research Hospital, Omaha, Nebraska 68131, and the
Department of Pediatric Oncology, Dana-Farber Cancer Institute
and Harvard Medical School, Boston, Massachusetts 02215
There are about 2.5 million glomeruli in the
kidneys each consisting of a barrel of glomerular basement membrane
surrounded by glomerular endothelial cells on the inside and glomerular
epithelial cells with established foot processes (podocytes) on the
outside. Defects in this filtration apparatus lead to glomerular
vascular leak or proteinuria. The role of vascular endothelial growth
factor (VEGF) in the regulation of glomerular vascular permeability is still unclear. Recent studies indicate that patients receiving anti-VEGF antibody therapy may have an increased incidence of proteinuria. In a different setting, pregnancies complicated by preeclampsia are associated with elevated soluble VEGF receptor 1 protein (sFlt-1), endothelial cell dysfunction and proteinuria. These
studies suggest that neutralization of physiologic levels of VEGF, a
key endothelial survival factor, may lead to proteinuria. In the
present study, we evaluated the potential of anti-VEGF neutralizing
antibodies and sFlt-1 in the induction of proteinuria. Our studies
demonstrate that anti-VEGF antibodies and sFlt-1 cause rapid glomerular
endothelial cell detachment and hypertrophy, in association with
down-regulation of nephrin, a key epithelial protein in the glomerular
filtration apparatus. These studies suggest that down-regulation or
neutralization of circulating VEGF may play an important role in the
induction of proteinuria in various kidney diseases, some forms of
cancer therapy and also in women with preeclampsia.
*
This work was supported in part by National Institutes of
Health (NIH) Grants DK-51711, DK 55001, by NIH renal Training Grant T32DK07199-25, and by research funds from the Program in Matrix Biology
at the Beth Israel Deaconess Medical Center.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
These authors contributed equally to this work.
§
Supported by Japan Research Foundation for Clinical Pharmacology
between 2001 and 2002. Currently supported by Stop & Shop Family
Pediatric Brain Tumor Program.
**
To whom correspondence should be addressed: Harvard Medical School,
Director, Program in Matrix Biology, DANA 514, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston MA 02215. Tel.: 617-667-0445; Fax: 617-975-5663; E-mail:
rkalluri@bidmc. harvard.edu.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. Nystrom, K. Hultenby, S. Ek, J. Sjolund, H. Axelson, K. Jirstrom, M. A. Saleem, K. Nilsson, and M. E. Johansson
CRIM1 is localized to the podocyte filtration slit diaphragm of the adult human kidney
Nephrol. Dial. Transplant.,
July 1, 2009;
24(7):
2038 - 2044.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. P. Thomas, J. I. Andrews, N. S. Raikwar, E. A. Kelley, F. Herse, R. Dechend, T. G. Golos, and K. Z. Liu
A Recently Evolved Novel Trophoblast-Enriched Secreted Form of fms-Like Tyrosine Kinase-1 Variant Is Up-Regulated in Hypoxia and Preeclampsia
J. Clin. Endocrinol. Metab.,
July 1, 2009;
94(7):
2524 - 2530.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nakagawa, T. Kosugi, M. Haneda, C. J. Rivard, and D. A. Long
Abnormal Angiogenesis in Diabetic Nephropathy
Diabetes,
July 1, 2009;
58(7):
1471 - 1478.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Perazella
Renal Vulnerability to Drug Toxicity
Clin. J. Am. Soc. Nephrol.,
July 1, 2009;
4(7):
1275 - 1283.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-W. Gu, R. D. Manning Jr., E. Young, M. Shparago, B. Sartin, and A. P. Bailey
Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats
Am J Physiol Regulatory Integrative Comp Physiol,
July 1, 2009;
297(1):
R142 - R148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Wang, S. Rana, and S. A. Karumanchi
Preeclampsia: The Role of Angiogenic Factors in Its Pathogenesis
Physiology,
June 1, 2009;
24(3):
147 - 158.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Shord, L. R. Bressler, L. A. Tierney, S. Cuellar, and A. George
Understanding and managing the possible adverse effects associated with bevacizumab
Am. J. Health Syst. Pharm.,
June 1, 2009;
66(11):
999 - 1013.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, and J. P. Spano
Management of hypertension in angiogenesis inhibitor-treated patients
Ann. Onc.,
May 1, 2009;
20(5):
807 - 815.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Satchell and F. Braet
Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier
Am J Physiol Renal Physiol,
May 1, 2009;
296(5):
F947 - F956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-C. Soria, C. Massard, and H. Izzedine
From Theoretical Synergy to Clinical Supra-Additive Toxicity
J. Clin. Oncol.,
March 20, 2009;
27(9):
1359 - 1361.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Ku, K. E. White, A. Dei Cas, A. Hayward, Z. Webster, R. Bilous, S. Marshall, G. Viberti, and L. Gnudi
Inducible Overexpression of sFlt-1 in Podocytes Ameliorates Glomerulopathy in Diabetic Mice
Diabetes,
October 1, 2008;
57(10):
2824 - 2833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Foster, S. C. Slater, J. Seckley, D. Kerjaschki, D. O. Bates, P. W. Mathieson, and S. C. Satchell
Vascular Endothelial Growth Factor-C, a Potential Paracrine Regulator of Glomerular Permeability, Increases Glomerular Endothelial Cell Monolayer Integrity and Intracellular Calcium
Am. J. Pathol.,
October 1, 2008;
173(4):
938 - 948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Plaisier, E. Streefland, P. Koolwijk, V.W.M. van Hinsbergh, F.M. Helmerhorst, and J.J.H.M. Erwich
Angiogenic Growth Factors and Their Receptors in First-Trimester Human Decidua of Pregnancies Further Complicated By Preeclampsia or Fetal Growth Restriction
Reproductive Sciences,
September 1, 2008;
15(7):
720 - 726.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Favaro, I. Miceli, B. Bussolati, M. Schimitt-Ney, P. Cavallo Perin, G. Camussi, and M. M. Zanone
Hyperglycemia Induces Apoptosis of Human Pancreatic Islet Endothelial Cells: Effects of Pravastatin on the Akt Survival Pathway
Am. J. Pathol.,
August 1, 2008;
173(2):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Levey, R. S. Bajwa, M. M. Picken, J. I. Clark, K. Barton, and D. J. Leehey
Thrombotic microangiopathy associated with sunitinib, a VEGF inhibitor, in a patient with factor V Leiden mutation
NDT Plus,
June 1, 2008;
1(3):
154 - 156.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Collino, B. Bussolati, E. Gerbaudo, L. Marozio, S. Pelissetto, C. Benedetto, and G. Camussi
Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells
Am J Physiol Renal Physiol,
May 1, 2008;
294(5):
F1185 - F1194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Haraldsson, J. Nystrom, and W. M. Deen
Properties of the Glomerular Barrier and Mechanisms of Proteinuria
Physiol Rev,
April 1, 2008;
88(2):
451 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. B. Kopp, M. G. Kabir, P. H. Backx, et al.
VEGF Inhibition and Renal Thrombotic Microangiopathy
N. Engl. J. Med.,
March 13, 2008;
358(11):
1129 - 1136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Rudge, J. Holash, D. Hylton, M. Russell, S. Jiang, R. Leidich, N. Papadopoulos, E. A. Pyles, A. Torri, S. J. Wiegand, et al.
Inaugural Article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade
PNAS,
November 20, 2007;
104(47):
18363 - 18370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Kapiteijn, A. Brand, J. Kroep, and H. Gelderblom
Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome
Ann. Onc.,
October 1, 2007;
18(10):
1745 - 1747.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ostendorf, A. S. De Vriese, and J. Floege
Renal side effects of anti-VEGF therapy in man: a new test system
Nephrol. Dial. Transplant.,
October 1, 2007;
22(10):
2778 - 2780.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Berkane, G. Lefevre, and A. Hertig
Angiogenic factors in preeclampsia: so complex, so simple?
Nephrol. Dial. Transplant.,
October 1, 2007;
22(10):
2753 - 2756.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Advani, D. J. Kelly, S. L. Advani, A. J. Cox, K. Thai, Y. Zhang, K. E. White, R. M. Gow, S. M. Marshall, B. M. Steer, et al.
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions
PNAS,
September 4, 2007;
104(36):
14448 - 14453.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. J. Ballermann and R. V. Stan
Resolved: Capillary Endothelium Is a Major Contributor to the Glomerular Filtration Barrier
J. Am. Soc. Nephrol.,
September 1, 2007;
18(9):
2432 - 2438.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Davis, A. Dei Cas, D. A. Long, K. E. White, A. Hayward, C.-H. Ku, A. S. Woolf, R. Bilous, G. Viberti, and L. Gnudi
Podocyte-Specific Expression of Angiopoietin-2 Causes Proteinuria and Apoptosis of Glomerular Endothelia
J. Am. Soc. Nephrol.,
August 1, 2007;
18(8):
2320 - 2329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. E. Stillman and S. A. Karumanchi
The Glomerular Injury of Preeclampsia
J. Am. Soc. Nephrol.,
August 1, 2007;
18(8):
2281 - 2284.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sugimoto, G. Grahovac, M. Zeisberg, and R. Kalluri
Renal Fibrosis and Glomerulosclerosis in a New Mouse Model of Diabetic Nephropathy and Its Regression by Bone Morphogenic Protein-7 and Advanced Glycation End Product Inhibitors
Diabetes,
July 1, 2007;
56(7):
1825 - 1833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Izzedine, I. Brocheriou, G. Deray, and O. Rixe
Thrombotic microangiopathy and anti-VEGF agents
Nephrol. Dial. Transplant.,
May 1, 2007;
22(5):
1481 - 1482.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Henao, P. W. Mathieson, M. A. Saleem, J. C. Bueno, and A. Cadavid
A novel renal perspective of preeclampsia: a look from the podocyte
Nephrol. Dial. Transplant.,
May 1, 2007;
22(5):
1477 - 1477.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hladunewich, S. A. Karumanchi, and R. Lafayette
Pathophysiology of the Clinical Manifestations of Preeclampsia
Clin. J. Am. Soc. Nephrol.,
May 1, 2007;
2(3):
543 - 549.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Cudmore, S. Ahmad, B. Al-Ani, T. Fujisawa, H. Coxall, K. Chudasama, L. R. Devey, S. J. Wigmore, A. Abbas, P. W. Hewett, et al.
Negative Regulation of Soluble Flt-1 and Soluble Endoglin Release by Heme Oxygenase-1
Circulation,
April 3, 2007;
115(13):
1789 - 1797.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. D. Garovic, S. J. Wagner, L. M. Petrovic, C. E. Gray, P. Hall, H. Sugimoto, R. Kalluri, and J. P. Grande
Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia
Nephrol. Dial. Transplant.,
April 1, 2007;
22(4):
1136 - 1143.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Xu, L. Zeng, H. Peng, S. Chen, J. Jones, T.-L. Chew, M. M. Sadeghi, Y. S. Kanwar, and F. R. Danesh
HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation
Am J Physiol Renal Physiol,
November 1, 2006;
291(5):
F995 - F1004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Allen, A. Adlakha, and P. R. Bergethon
Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer.
Arch Neurol,
October 1, 2006;
63(10):
1475 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Kalluri
Proteinuria with and without Renal Glomerular Podocyte Effacement
J. Am. Soc. Nephrol.,
September 1, 2006;
17(9):
2383 - 2389.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Guan, G. Villegas, J. Teichman, P. Mundel, and A. Tufro
Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP
Am J Physiol Renal Physiol,
August 1, 2006;
291(2):
F422 - F428.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Kodama, Y. Kitta, T. Nakamura, H. Takano, K. Umetani, D. Fujioka, Y. Saito, K.-i. Kawabata, J.-e. Obata, A. Mende, et al.
Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction
J. Am. Coll. Cardiol.,
July 4, 2006;
48(1):
43 - 50.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Sugimoto, T. M. Mundel, M. Sund, L. Xie, D. Cosgrove, and R. Kalluri
Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease
PNAS,
May 9, 2006;
103(19):
7321 - 7326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E.J. Reinders, T. J. Rabelink, and D. M. Briscoe
Angiogenesis and Endothelial Cell Repair in Renal Disease and Allograft Rejection
J. Am. Soc. Nephrol.,
April 1, 2006;
17(4):
932 - 942.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Eremina, S. Cui, H. Gerber, N. Ferrara, J. Haigh, A. Nagy, M. Ema, J. Rossant, S. Jothy, J. H. Miner, et al.
Vascular Endothelial Growth Factor A Signaling in the Podocyte-Endothelial Compartment Is Required for Mesangial Cell Migration and Survival
J. Am. Soc. Nephrol.,
March 1, 2006;
17(3):
724 - 735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S.R. Maharaj, M. Saint-Geniez, A. E. Maldonado, and P. A. D'Amore
Vascular Endothelial Growth Factor Localization in the Adult
Am. J. Pathol.,
February 1, 2006;
168(2):
639 - 648.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kamba, B. Y. Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M. R. Mancuso, S. M. Norberg, S. M. O'Brien, R. B. Davis, L. C. Gowen, et al.
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
Am J Physiol Heart Circ Physiol,
February 1, 2006;
290(2):
H560 - H576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Baffert, T. Le, B. Sennino, G. Thurston, C. J. Kuo, D. Hu-Lowe, and D. M. McDonald
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
Am J Physiol Heart Circ Physiol,
February 1, 2006;
290(2):
H547 - H559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Shibata, A. Rajakumar, R. W. Powers, R. W. Larkin, C. Gilmour, L. M. Bodnar, W. R. Crombleholme, R. B. Ness, J. M. Roberts, and C. A. Hubel
Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor
J. Clin. Endocrinol. Metab.,
August 1, 2005;
90(8):
4895 - 4903.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Tissot van Patot, G. Leadbetter, L. E. Keyes, J. Bendrick-Peart, V. E. Beckey, U. Christians, and P. Hackett
Greater free plasma VEGF and lower soluble VEGF receptor-1 in acute mountain sickness
J Appl Physiol,
May 1, 2005;
98(5):
1626 - 1629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. McGrath-Morrow, C. Cho, C. Cho, L. Zhen, D. J. Hicklin, and R. M. Tuder
Vascular Endothelial Growth Factor Receptor 2 Blockade Disrupts Postnatal Lung Development
Am. J. Respir. Cell Mol. Biol.,
May 1, 2005;
32(5):
420 - 427.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Nangaku, S. J. Shankland, and W. G. Couser
Cellular Response to Injury in Membranous Nephropathy
J. Am. Soc. Nephrol.,
May 1, 2005;
16(5):
1195 - 1204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Zhang, E. Galardi, M. Duquette, M. Delic, J. Lawler, and S. Parangi
Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res.,
March 15, 2005;
11(6):
2337 - 2344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Watanabe, A. J. Mamelak, E. Weiss, B. Wang, I. Freed, A. K. Brice, L. Wachtman, K. L. Gabrielson, N. Yokota, D. J. Hicklin, et al.
Anti-Vascular Endothelial Growth Factor Receptor-2 Antibody Accelerates Renal Disease in the NZB/W F1 Murine Systemic Lupus Erythematosus Model
Clin. Cancer Res.,
January 1, 2005;
11(1):
407 - 409.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Korc
Targeted Therapeutics in Pancreatic Cancer: A Ray of Hope
Clin. Cancer Res.,
January 1, 2005;
11(1):
410 - 411.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Foster, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper
Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes
Am J Physiol Renal Physiol,
January 1, 2005;
288(1):
F48 - F57.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Karumanchi and Y. Bdolah
Hypoxia and sFlt-1 in Preeclampsia: The "Chicken-and-Egg" Question
Endocrinology,
November 1, 2004;
145(11):
4835 - 4837.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Hertig, N. Berkane, G. Lefevre, K. Toumi, H.-P. Marti, J. Capeau, S. Uzan, and E. Rondeau
Maternal Serum sFlt1 Concentration Is an Early and Reliable Predictive Marker of Preeclampsia
Clin. Chem.,
September 1, 2004;
50(9):
1702 - 1703.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. H. Lapchak, M. Melter, S. Pal, J. A. Flaxenburg, C. Geehan, M. H. Frank, D. Mukhopadhyay, and D. M. Briscoe
CD40-induced transcriptional activation of vascular endothelial growth factor involves a 68-bp region of the promoter containing a CpG island
Am J Physiol Renal Physiol,
September 1, 2004;
287(3):
F512 - F520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ferrara
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Endocr. Rev.,
August 1, 2004;
25(4):
581 - 611.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-G. Cui, R. R. Foster, M. Saleem, P. W. Mathieson, D. A. Gillatt, D. O. Bates, and S. J. Harper
Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein
Am J Physiol Renal Physiol,
April 1, 2004;
286(4):
F767 - F773.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. C. Satchell, K. L. Anderson, and P. W. Mathieson
Angiopoietin 1 and Vascular Endothelial Growth Factor Modulate Human Glomerular Endothelial Cell Barrier Properties
J. Am. Soc. Nephrol.,
March 1, 2004;
15(3):
566 - 574.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|